RCUS
Arcus Biosciences Inc
NYSE: RCUS · HEALTHCARE · BIOTECHNOLOGY
$24.13
-2.70% today
Updated 2026-04-29
Market cap
$3.03B
P/E ratio
—
P/S ratio
12.27x
EPS (TTM)
$-3.29
Dividend yield
—
52W range
$7 – $29
Volume
1.3M
Arcus Biosciences Inc (RCUS) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$24.13
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$184.95
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.4B | $0.1B | $0.1B | $0.3B | $0.2B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -142.90%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.